Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.59 |
| ▸ | DRD3 | P35462 | 7/20 | 0.59 |
| ▸ | DRD4 | P21917 | 6/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | DRD5 | P21918 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.47 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1244917 | 0.99 | DRD2 (0.58) | DRD2DRD3DRD4DRD1DRD5 | |
| Acetic Acid SCHEMBL28545033 | 0.94 | DRD2 (0.53) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL1246145 | 0.87 | DRD2 (0.51) | DRD2DRD3DRD4DRD1ADRB1 | |
| SCHEMBL13437595 | 0.86 | DRD2 (0.56) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL12119317 | 0.84 | DRD2 (0.56) | DRD2DRD3DRD4DRD1ADRB1 | |
| SCHEMBL9909663 | 0.82 | ADRB1 (0.52) | DRD2DRD3DRD4DRD1ADRB1 | |
| SCHEMBL28545030 | 0.78 | NR3C2 (0.45) | DRD2DRD3DRD4DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL4022568 | 0.77 | ADRB1 (0.55) | DRD2DRD3DRD4DRD1ADRB1 | |
| SCHEMBL18122621 | 0.76 | ADRB1 (0.68) | ADRB1ADRB2 | |
| SCHEMBL3225165 | 0.76 | ADRB1 (0.68) | ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109195975-B | Diazaspiro [5.5] undecane derivative and application thereof | 四川海思科制药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-107849014-B | Biphenyl derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-07-09 | — | — | CN | disclosed |
| WO-2017107877-A1 | BIPHENYL DERIVATIVE AND PREPARATION METHOD AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2017-06-29 | — | — | WO | disclosed |
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160031838-A1 | SMYD2 INHIBITORS | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031838-A1 | SMYD2 INHIBITORS | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031838-A1 | SMYD2 INHIBITORS | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
| CN-102625808-B | Spirocyclic amide derivatives | ASTRAZENECA AB | 2014-08-27 | — | — | CN | disclosed |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| WO-2009154557-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154557-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| EP-2094646-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031838-A1 | SMYD2 INHIBITORS | SMYD2, SMYD3, NSD1 | DRD2 1794/4885DRD3 1951/4885DRD4 2632/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | DRD2 18/4885DRD3 46/4885DRD4 76/4885 |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | GPR119, CYP4B1, CYP4A11 | DRD2 1004/4885DRD3 875/4885DRD4 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.